Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study - PubMed (original) (raw)

Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study

Jose F Camargo et al. Blood Adv. 2020.

Abstract

  1. Shingrix is poorly immunogenic following allogeneic hematopoietic cell transplantation independent of age, CD4, and B-cell recovery.
  2. In hematopoietic cell transplantation recipients with antibody response to the vaccine, varicella zoster virus reactivation risk is not null.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: K.V.K. has served as an ad hoc consultant to Kite/Gilead, Novartis, Celgene, Atara, Kiadis, Kadmon, and Takeda. M.I.M. has received research funding from Merck. The remaining authors declare no competing financial interests.

Figures

Figure 1.

Figure 1.

Flowchart for study subject selection.

References

    1. Xue E, Xie H, Leisenring WM, et al. High incidence of herpes zoster after cord blood hematopoietic cell transplant despite longer duration of antiviral prophylaxis [published online ahead of print 9 March 2020]. Clin Infect Dis. 10.1093/cid/ciaa222. -DOI -PMC -PubMed
    1. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study. Blood. 2006;107(5):1800-1805. -PMC -PubMed
    1. Bastidas A, de la Serna J, El Idrissi M, et al. ; ZOE-HSCT Study Group Collaborators . Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123-133. -PMC -PubMed
    1. Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921-2929. -PMC -PubMed
    1. Dagnew AF, Ilhan O, Lee WS, et al. ; Zoster-039 study group . Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988-1000. -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources